Last reviewed · How we verify
NCT02478645
Dose-ranging Study of Ramosetron for the Prevention of Nausea and Vomiting After Gynecologic Laparoscopic Surgery
Phase 4 trial testing ramosetron 0.3 in Postoperative Nausea and Vomiting in 177 participants. Completed in 6 February 2016.
6 February 2016
Quick facts
| Lead sponsor | Yonsei University |
|---|---|
| Phase | Phase 4 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | triple |
| Primary purpose | other |
| Enrollment | 177 |
| Start date | 19 June 2015 |
| Primary completion | 6 February 2016 |
| Estimated completion | 6 February 2016 |
| Sites | 1 location across South Korea |
Drugs / interventions tested
- ramosetron 0.3 — full drug profile →
- ramosetron 0.45 — full drug profile →
- ramosetron 0.6 — full drug profile →
Conditions studied
- Postoperative Nausea and Vomiting — all drugs for Postoperative Nausea and Vomiting →
Sponsor
Yonsei University
Who can join
Adults 20 to 70, any sex, with Postoperative Nausea and Vomiting. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Many patients receiving opioid based analgesia after gynecologic laparoscopic surgery experience postoperative nausea and vomiting (PONV) despite prophylaxis and treatment with HT3 receptor antagonists. Although a high dose of ramosetron can cause adverse effects such as headache or dizziness, the minimal effective dose of ramosetron in a high-risk patients is unknown. The aim of this study is to determine the effective dose of ramosetron for prophylaxis of PONV in a high-risk patients receiving intravenous opioid-based patient-controlled analgesia after gynecological laparoscopic surgery.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Dose-Ranging Study of Ramosetron for the Prevention of Nausea and Vomiting after Laparoscopic Gynecological Surgery: A Prospective Randomized Study.
Cho JS, Kim SW, Lee S, Yoo YC. · · 2019 · cited 5× · PMID 31835896 · DOI 10.3390/jcm8122188
Verify or expand the search:
- PubMed search for NCT02478645
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Postoperative Nausea and Vomiting
Currently open trials in the same condition.
- NCT07336160 — ERAS-Based Preoperative Nutrition and Fasting in Total Knee Arthroplasty · NA · recruiting
- NCT07242209 — Sugammadex and Menstrual Cycle in Postoperative Nausea and Vomiting · recruiting
- NCT07244575 — Association Between Preoperative Metformin Exposure and Postoperative Nausea and Vomiting in Patients Undergoing General · recruiting
- NCT06632184 — Peritoneal Lavage Using Saline or Saline With Ondansetron for Pain Control After Laparoscopic Cholecystectomy · Phase 4 · active not recruiting
- NCT07271147 — Effects of taVNS Combined With Dexmedetomidine on POVN · NA · recruiting
Other Yonsei University trials
Trials by the same sponsor.
- NCT07547592 — Gemcitabine and Docetaxel With or Without Bevacizumab (Onbevzi) for Soft Tissue Sarcoma · Phase 2 · not yet recruiting
- NCT07524101 — Moderate-Intensity Statin Plus Ezetimibe in CKD and ASCVD · NA · not yet recruiting
- NCT07506629 — Adductor Canal Block Methods in Bilateral Total Knee Arthroplasty · NA · not yet recruiting
- NCT07515716 — Effects of High Flow Humidified Oxygen on Umbilical Artery Acid-base Balance in Cesarean Section Under Spinal Anesthesia · NA · not yet recruiting
- NCT07507188 — Collaborative Clinical-translational Cohort of Amivantamab Plus Lazertinib and Amivantamab Plus Chemotherapy in Patients · Phase 2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT02478645 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Yonsei University
- Last refreshed: 25 January 2017
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02478645.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing